Furthermore, Zehua et al. reported that disruption of the MEK/ERK/c-Myc central metabolic axis within tumor ECs is sufficient to halt tumor growth; inhibiting this central metabolic axis has positive implications for tumor ECs treatments [42]. Here, MYC is linked to neoplasm.